Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

Original reporting
Published Oct 27, 2026, 2:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 4:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AVBP
Bullish
high confidence
Mentioned
$AVBP
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AVBPBullishMed
01

Why it matters

The upgrade may trigger short‑term buying pressure, but investors should monitor Phase 1b results in H1 2027 for confirmation.

02

Market read

The article provides fresh analyst coverage and early clinical data, offering a new trading angle for AVBP.

03

What to watch

Potential regulatory hurdles and competition in colorectal cancer therapies could limit upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Truist's upgrade follows release of Phase 1 data for ARR-217, a CDH17 antibody‑drug conjugate targeting metastatic colorectal cancer.

Company-level read

Ticker impact

$AVBPBullishHigh confidence
Context

Truist raised its price target on AVBP to $21 citing encouraging Phase 1 data for the ARR-217 drug candidate.

Expected impact

likely upward pressure as the market prices in the higher target and favorable data.

Evidence & confidence

The new target reflects a material reassessment of valuation after the 44.8% response rate data, which can attract buying interest.

Market effects

Positive early data may lift sentiment for the broader biotech sector.

Limited to US-listed biotech investors.

Modest, as the drug is early‑stage and impacts only niche oncology investors.

Counterpoint

The data are preliminary and durability is unproven; the stock may be overvalued at $21.

Key entities

  • ArriVent BioPharma

    Biotech firm developing ARR-217.

  • Truist Securities

    Equity research firm that raised the price target.

Related articles

$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

$AVBPMed

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

$AVBPMedAI 9/10

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.

$AVBPHighAI 9/10

ArriVent BioPharma Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data

ArriVent BioPharma reported Phase 1 data for ARR-217, showing a 44.8% response rate at 6 mg/kg in pretreated colorectal cancer patients. The disease control rate was 93.1% at this dose. At 4 mg/kg and higher, the response rate was 34.2% with a 91.8% disease control rate. Grade 3 or higher adverse events occurred in 30.1% of patients. The company plans to advance to Phase 1b dose optimization.